Profile photo

Cardiology With Kevin M. Alexander, MD, FACC, FHFSA

Cardiology

Dr. Alexander is an advanced heart failure-trained cardiologist and an Assistant Professor of Cardiovascular Medicine at Stanford University School of Medicine. He specializes in the management of advanced heart failure and transplant cases, seeing a wide range of patients. He also has an active research laboratory, studying various forms of heart failure.

Wild-Type ATTR: Significance and Impact

Dear readers,

This week, my collection on transthyretin amyloid (ATTR) continues with a discussion from Dr. Esther Gonzalez Lopez. In the study, she discusses the significance of wild-type ATTR in HFpEF and its impact on patients. This disease state must be less underestimated as we continue to treat our patients.

In addition, I included an expert assessment on the impact of ATTR-CM from Radcliffe and more.

Until next week,
Kevin Alexander, MD

Articles
  • Mashup Score: 4
    • Profile photo of radcliffeCARDIO
      radcliffeCARDIO

      📊 Dr Esther González López reveals that 13% of HFpEF patients over 60 with left ventricular hypertrophy (≥12 mm) have wild-type ATTR cardiac amyloidosis. This study highlights the significant role of wild-type ATTR in HFpEF often underestimated but impacting many patients… https://t.co/JoEEbr057w https://t.co/DKnj988mZE

      Read the original tweet here

    Tweet Tweets with this article
  • Mashup Score: 4
    The Bigger Picture: An Expert Assessment on the True Impact of ATTR-CM - 12 day(s) ago

    Read the full article here

    Tweet Tweets with this article
    • Profile photo of radcliffeCARDIO
      radcliffeCARDIO

      🚩 What are the "red flags" to look out for when diagnosing cardiac amyloidosis? 👉 Watch this #ATTR-CM series to learn how HCPs can drive early detection for optimal results 🔗 https://t.co/9mG7pNIVzg This activity is supported by an unrestricted educational grant from… https://t.co/WOVoxKQ17w https://t.co/9okV9Zkgxq

  • Mashup Score: 12
    Pharmacological Management of Transthyretin Amyloid Cardiomyopathy: A scoping review - 12 day(s) ago

    Read the full article here

    Tweet Tweets with this article
    • Profile photo of pyrpyris
      pyrpyris

      💊 #Pharmacological Management of Transthyretin Amyloid (ATTR) #Cardiomyopathy A new scoping review just published at #EHJPharmacotherapy @ESC_Journals Available➡️ https://t.co/6PmVpwOtt8 @EditorEHJCVP @ESCardioNews #CardioEd #Cardio #CardioTwitter #ATTR #ESCYoung #MedEd https://t.co/q1cu6ZSgNy

  • Mashup Score: 6
    New Horizons in Amyloidosis (NHA) - 12 day(s) ago

    Read the full article here

    Tweet Tweets with this article
    • Profile photo of radcliffeCARDIO
      radcliffeCARDIO

      👋 New Horizons in Amyloidosis (NHA) is now available on-demand ➡️ https://t.co/6VQU6MoXeR Catch up on key sessions on cardiac amyloidosis, cardiac MRI, ATTR-CM, HF and more! #ATTR #HF #CardioTwitter @rodney_falk https://t.co/hwtP9AK3uP

  • Mashup Score: 23
    • Profile photo of omarsiddiqi
      omarsiddiqi

      Renal dysfunction in ATTR wild-type #amyloidosis: is it always cardio-renal syndrome and renal congestion? Interesting report of ATTR wild type renal involvement by #tracyjoshi @dmgopalcardio @AshuNephro @a_staron of @BU_Amyloidosis @BUcards @The_BMC @vsanchorawala https://t.co/rjq8RE9HcM

      Read the original tweet here

    Tweet Tweets with this article